We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.
Click Target For More Info
| Target | Indication | Discovery | Preclinical | Phase 1 | |
| MC2 | Orphan endocrine disorders | ||||
| SLC15A4 | Lupus and other IFN-opathies | ||||
| GPR65 | Inflammatory bowel disease | ||||
| Gasdermin | Broad immunology | ||||
| cGAS | Broad immunology | ||||
MC2
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
SLC15A4
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
GPR65
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.
Gasdermin
First-in-class Gasdermin D inhibitors – a pipeline in a product.
cGAS
Best-in-class cGAS inhibitor